Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboxypeptidase X, M14 family member 2 (CPXM2) is a protein encoded by the CPXM2 gene in humans, structurally related to M14 metallocarboxypeptidases but lacking the active site and zinc-binding residues required for enzymatic activity[5]. It is not an active carboxypeptidase but is predicted to participate in cell-cell interactions and extracellular matrix organization. CPXM2 is expressed in various tissues and is upregulated in cardiac hypertrophy, implicating it as a potential therapeutic target for cardiac remodeling and failure. Mutations and dysregulation of CPXM2 are associated with diseases such as ectodermal dysplasia and chromosomal duplication syndromes. Currently, no drugs directly target CPXM2, and its precise biological function remains under investigation, with recent knockout animal models supporting its role in cardiac disease risk and progression[5][1][3][2][4].
Not established (no known drugs; molecular modulation would likely target gene expression, cell signaling, or protein-protein interaction; knockout models show protection against cardiac hypertrophy, suggesting a target for future therapies)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carboxypeptidase X, M14 family member 2 (CPXM2).